Physicians' Academy for Cardiovascular Education

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal



Prof. Frederick Raal (University of Witwatersrand, Johannesburg, South Africa)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
 
ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.